Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q

Diagnostic Molecular Pathology

Volumn 14, Issue 3, 2005, Pages 177-182

  Boensch, Marc ^a   Oberthuer, André ^a   Fischer, Matthias ^a   Skowron, Matthias ^a   Oestreich, Joern ^a   Berthold, Frank ^a   Spitz, Ruediger ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Chromosomal aberrations; Neuroblastoma; Quantitative RT PCR

Indexed keywords

GENOMIC DNA; MOLECULAR MARKER; PARAFFIN;

ARTICLE; CELL POPULATION; CHROMOSOME 11Q; CHROMOSOME 1P; CHROMOSOME ABERRATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE TARGETING; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MYCN GENE; NEUROBLASTOMA; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING;

CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 11; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE DELETION;

EID: 25844431615     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000176767.10800.17     Document Type: Article

References (32)

1. Schwab M, Westermann F, Hero B, et al. Neuroblastoma: Biology and molecular and chromosomal pathology. Lancet Oncol. 2003;4:472-480.
2. Brodeur GM, Seeger BC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224:1121-1124.
3. White PS, Maris JM, Beltinger C, et al. A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci USA. 1995;92:5520-5524.
4. Maris JM, Weiss MJ, Guo C, et al. Loss of heterozygosity at 1p36 independently predicts for disese progression but not decreased overall survival probability in neuroblastoma patients: A Children's Cancer Group study. J Clin Oncol. 2000;18:1888-1899.
5. Berthold F. NB 2004 Trial protocol for risk adapted treatment of children with neuroblastoma. Protocol of the German Neuroblastoma trial 2004 published by Berthold F. in Cologne, Germany. Version 1.00.
6. Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr. 2005;17:7-13.
7. Guo C, White SW, Weiss MJ, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene. 1999;18:4948-4957.
8. Spitz R, Hero B, Ernestus K, et al. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4S Neuroblastoma. Clin Cancer Res. 2003;9:52-58.
9. De Preter K, Speleman F, Combaret V, et al. Quantification of MYCN, DDX 1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. Mod Pathol. 2002;2:159-166.
10. Morowitz M, Shusterman S, Mosse Y, et al. Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction. Mod Pathol. 2003;16:1248-1256.
11. Spitz R, Hero B, Ernestus K, et al. Gain of distal chromosome arm 17q in not associated with poor prognosis in neuroblastoma. Clin Cancer Res. 2003;9:4835-4840.
12. Spitz R, Hero B, Ernestus K, et al. FISH analyses for alterations in chromosome 1, 2, 3 and 11 define high-risk groups in neuroblastoma. Med Pediatr Oncol. 2003;41:30-35.
13. Simon T, Spitz R, Faldum A, et al. New definition of low-risk neuroblastoma using stage, age and 1p and MYCN status. J Pediatr Hematol Oncol. 2004;26:791-796.
14. Chan MW, Chu ES, To KF, et al. Quantitative detection of methylated SOCS-1, a tumor suppressor gene, by a modified protocol of quantitative real time methylation-specific PCR using SYBR-green and its use in early gastric cancer detection. Biotechnol Lett. 2004;26:1289-1293.
15. Krams M, Parwaresch R, Sipos B, et al. Expression of the c-kit receptor characterizes a subset of neuroblastomas with favorable prognosis. Oncogene. 2004;23:588-595.
16. Tajiri T, Liu X, Thompson PM, et al. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1g is reduced in neuroblastomas with unfavorable biological features. Clin Cancer Res. 2003;9:3345-3355.
17. Cheung IY, Lo Piccolo MS, Kushner BH, et al. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: Clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol. 2003;21:1087-1093.
18. Cohn SL, London WB, Huang D, et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol. 2000;18:3604-3613.
19. Lambooy HH, Gidding C, van den Huyel LP, et al. Real-time analysis of tripsine hydroxylase gene expression: A sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma. Clin Cancer Res. 2003;9:812-819.
20. Dotsch J, Harmjanz J, Christiansen H, et al. Gene expression of neuronal nitric oxide synthase and adrenomedullin in human neuroblastoma using real-time PCR. Int J Cancer. 2000;88:172-175.
21. Kees UR, Terry PA, Everett J, et al. Detection of hemizygous deletion in genomic DNA from leukaemia specimens for the diagnosis of patients. Leuk Res. 2005;29:165-171.
22. Ayegard JS, Knowles MA. Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification. J Mol Diagn. 2004;6:356-365.
23. Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol. 2004;22:4157-4164.
24. Raggi CC, Bagnoni ML, Tonini GP, et al. Real-time quantitative PCR for the measurement of MYCN amplification in human neuroblastoma with the TaqMan detection system. Clin Chem. 1999;45:1918-1924.
25. Melegh Z, Bálint I, Tóth E, et al. Detection of N-MYC Amplification in Neuroblastoma by comparative, in situ and, real-time polymerase chain reaction. Pediatr Pathol Mol Med. 2003;22:213-222.
26. Scaruffi P, Parodi S, Mazzocco K, et al. Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridisation. Mol Diagn. 2004;8:93-100.
27. Ambros IM, Zellner A, Roald B, et al. Roly of ploidy, chromosome 1p, Schwann cells in the maturation of neuroblastoma. N Engl J Med. 1996;334:1505-1511.
28. Vandesompele J, Van Roy N, Van Gele M, et al. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer. 1998;23:141-152.
29. Brinkschmidt C, Christiansen H, Terpe HJ, et al. Comparative genomic hybridization (CGH) analysis of neuroblastomas-An important methodologic approach in paediatric tumour pathology. J Pathol. 1997;181:394-400.
30. Mathew P, Valentine MB, Bowman LC, et al. Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridisation: A pediatric oncology group study. Neoplasia. 2001;3:105-109.
31. Ambros IM, Benard J, Boavida M, et al. Quality assessment of genetic markers used for therapy stratification. J Clin Oncol. 2003;1:2077-2084.
32. Lehmann U, Kreipe H. Real-Time PCR Analysis of DNA and RNA extracted from formalin-fixed paraffin-embedded biopsies. Methods. 2001;25:409-418.